Aethlon Medical, Inc. Earnings Recaps
Q3 2026
Feb 13, 2026
Aethlon Medical demonstrated steady progress in its Hemopurifier platform amidst ongoing clinical trials and strategic operational efficiencies in Q3 FY2026.
Key takeaways
- Continued enrollment and treatment efforts in the Australian oncology trial indicate positive patient interest and safety outcomes, with no serious adverse events reported so far.
- Ongoing operating expense reductions year-to-date reflect disciplined cost management and financial prudence.
- Advancements in EV research support the Hemopurifier's potential as a multi-indication therapeutic platform, broadening its future applications.
- Collaboration with Stavro on simplifying the Hemopurifier treatment procedure aims to enhance clinical flexibility and accessibility.
- Exploration of the Hemopurifier's role in addressing other health conditions, including Long COVID and various autoimmune diseases, suggests opportunities for pipeline expansion.